

June 23, 2021

## Q4FY21 Result Update

Change in Estimates |  Target |  Reco

### Change in Estimates

	Current		Previous	
	FY22E	FY23E	FY22E	FY23E
Rating	BUY		ACCUMULATE	
Target Price	208		110	
Sales (Rs. m)	164,921	192,866	154,707	176,820
% Chng.	6.6	9.1		
EBITDA (Rs. m)	34,947	41,833	29,688	34,816
% Chng.	17.7	20.2		
EPS (Rs.)	10.2	12.2	8.4	9.9
% Chng.	21.1	23.6		

### Key Financials - Standalone

Y/e Mar	FY20	FY21	FY22E	FY23E
Sales (Rs. m)	129,211	140,638	164,921	192,866
EBITDA (Rs. m)	27,301	31,811	34,947	41,833
Margin (%)	21.1	22.6	21.2	21.7
PAT (Rs. m)	17,938	20,654	24,865	29,825
EPS (Rs.)	7.4	8.5	10.2	12.2
Gr. (%)	(6.9)	15.1	20.4	19.9
DPS (Rs.)	2.4	4.0	3.3	3.9
Yield (%)	1.4	2.4	1.9	2.3
RoE (%)	19.0	20.0	21.3	22.1
RoCE (%)	25.2	27.2	26.7	27.6
EV/Sales (x)	3.1	2.7	2.3	1.9
EV/EBITDA (x)	14.5	12.0	10.7	8.7
PE (x)	22.9	19.9	16.5	13.8
P/BV (x)	4.2	3.8	3.3	2.8

### Key Data

BAJE.BO | BHE IN

52-W High / Low	Rs.170 / Rs.81
Sensex / Nifty	52,306 / 15,687
Market Cap	Rs.411bn/ \$ 5,527m
Shares Outstanding	2,437m
3M Avg. Daily Value	Rs.4407.06m

### Shareholding Pattern (%)

Promoter's	51.14
Foreign	10.25
Domestic Institution	31.30
Public & Others	7.31
Promoter Pledge (Rs bn)	-

### Stock Performance (%)

	1M	6M	12M
Absolute	6.9	46.0	102.3
Relative	3.3	29.6	37.0

### Viral Shah

viralshah@plindia.com | 91-22-66322250

### Nilesh Soni

nileshsoni@plindia.com |

## Strong quarter; Robust Outlook

### Quick Pointers:

- Strong execution and cost rationalization measures led margin expansion by 299bps YoY to 28.5%; OI of ~Rs155bn in FY21 despite pandemic.
- Given strong order backlog and tender pipeline, management guided revenue growth of 15-17% with EBIDTA margin of 20-22%.

**Bharat Electronic (BEL) reported stellar quarterly performance above our and street estimates, led by strong execution and cost optimization measures. Revenue grew 19% YoY mainly due to strong execution in large value projects such as Akash weapon system and LRSAM. Despite pandemic, OI came in at Rs155mn (up 17%) in FY21. Ordering pipeline remains robust across segments such as electronic warfare system (~Rs150bn opportunity size), army equipment's like Akash weapon system, QRSAM, LRSAM, MRSAM (Rs250-300bn) and naval equipments like surveillance system, radars, navigation system (~Rs150-200bn) etc. Given strong bid pipeline (~Rs250bn), management guided OI of Rs150-170bn with healthy revenue growth of 15-20% YoY and EBITDA margins in 20-22% range for FY22. Apart from gaining market share in defense segment, management is also diversifying in non-defense verticals such as EV, metros, electronic warfare, healthcare, etc. expecting to reach 25% of total revenues over next 2-3 years.**

**Given 1) strong order backlog, 2) tender pipeline, 3) diversification into newer business verticals like EV, ventilator, oxygen concentrator, dialysis, metros, aerospace, etc. and 4) solid management guidance we have revised upwards our earnings estimate by 21%/24% for FY22/FY23E. The stock is currently trading at 16.5x/13.8x FY22E/23E. We roll over to FY23 estimates and upgrade to 'Buy' rating on the stock from Accumulate, with revised TP of Rs208 (Rs110 earlier). Further we have raised our PE multiple to 17x (avg. of 10 years) from 13x earlier given improved visibility on order inflows, ramp up in execution and diversification into newer business vertical.**

**Strong execution and cost optimization measures boost margin:** Sales reported strong growth of 19% YoY to Rs69bn vs (PLe ~Rs65.3bn) driven by healthy execution. EBITDA grew by 32.9% YoY to Rs19.7bn vs (PLe ~Rs12.5bn) with EBITDA margins expanding by 299 bps YoY to 28.5% due to lower employee cost (down 16.8% YoY) and other expenses (down 10.4% YoY). PBT was up 36.5% YoY to Rs19.3bn, led by higher other income (up 102% YoY) and strong operating performance. PAT came in at Rs13.5bn (up 30.7% YoY) vs (PLe~Rs9.6bn).

**Strong order book provides revenue visibility:** Despite pandemic OI came in at Rs155nm (up 17%) in FY21. Given healthy pipeline, management guided for order inflows to the tune of Rs150-170bn (Army and Navy Rs40bn-50bn. Airforce Rs80-90bn and Non-defence Rs20-30bn). OB stands strong at Rs534bn (3.8x TTM revenue) of which smart city and home land security orders stand at Rs50bn plus.

**Exhibit 1: Cost optimization measures boost margin**

Y/e March	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21	YoY gr. (%)	QoQ gr. (%)	FY21	FY20	YoY gr. (%)
<b>Revenue</b>	<b>58,058</b>	<b>16,706</b>	<b>31,887</b>	<b>22,962</b>	<b>69,083</b>	<b>19.0</b>	<b>200.9</b>	<b>140,638</b>	<b>129,211</b>	<b>8.8</b>
<b>Total Revenues</b>	<b>58,058</b>	<b>16,706</b>	<b>31,887</b>	<b>22,962</b>	<b>69,083</b>	<b>19.0</b>	<b>200.9</b>	<b>140,638</b>	<b>129,211</b>	<b>8.8</b>
<b>Expenditure</b>	<b>43,233</b>	<b>15,239</b>	<b>25,652</b>	<b>18,559</b>	<b>49,378</b>	<b>14.2</b>	<b>166.1</b>	<b>108,827</b>	<b>101,910</b>	<b>6.8</b>
<i>as % of sales</i>	<i>74.5</i>	<i>91.2</i>	<i>80.4</i>	<i>80.8</i>	<i>71.5</i>			<i>77.4</i>	<i>78.9</i>	
Consumption of RM	33,130	8,234	17,540	11,811	40,693	22.8	244.5	78,278	71,052	10.2
<i>as % of sales</i>	<i>57.1</i>	<i>49.3</i>	<i>55.0</i>	<i>51.4</i>	<i>58.9</i>			<i>55.7</i>	<i>55.0</i>	
Employee Cost	5,747	5,117	4,969	4,539	4,782	(16.8)	5.3	19,407	20,575	(5.7)
<i>as % of sales</i>	<i>9.9</i>	<i>30.6</i>	<i>15.6</i>	<i>19.8</i>	<i>6.9</i>			<i>13.8</i>	<i>15.9</i>	
Other expenditure	4,356	1,888	3,143	2,209	3,903	(10.4)	76.7	11,142	10,283	8.4
<i>as % of sales</i>	<i>7.5</i>	<i>11.3</i>	<i>9.9</i>	<i>9.6</i>	<i>5.6</i>			<i>7.9</i>	<i>8.0</i>	
<b>EBITDA</b>	<b>14,826</b>	<b>1,467</b>	<b>6,235</b>	<b>4,404</b>	<b>19,706</b>	<b>32.9</b>	<b>347.5</b>	<b>31,811</b>	<b>27,301</b>	<b>16.5</b>
Depreciation	950	888	914	945	917	(3.5)	(3.0)	3,663	3,496	4.8
<b>EBIT</b>	<b>13,875</b>	<b>579</b>	<b>5,321</b>	<b>3,459</b>	<b>18,789</b>	<b>35.4</b>	<b>443.3</b>	<b>28,148</b>	<b>23,805</b>	<b>18.2</b>
Other Income	283	184	274	231	572	102.0	147.3	1,261	1,019	23.7
Interest	16	1	3	2	56	244.7	3,368.8	61	33	86.5
<b>PBT</b>	<b>14,142</b>	<b>762</b>	<b>5,592</b>	<b>3,688</b>	<b>19,305</b>	<b>36.5</b>	<b>423.4</b>	<b>29,348</b>	<b>24,792</b>	<b>18.4</b>
Total Tax	3,797	221	1,622	1,070	5,782	52.3	440.5	8,694	6,853	26.9
<b>Adjusted PAT</b>	<b>10,345</b>	<b>541</b>	<b>3,971</b>	<b>2,619</b>	<b>13,524</b>	<b>30.7</b>	<b>416.5</b>	<b>20,654</b>	<b>17,938</b>	<b>15.1</b>
(Profit)/loss from JV's/Ass/MI	-	-	-	-	-	-	-	-	-	-
<b>PAT after MI</b>	<b>10,345</b>	<b>541</b>	<b>3,971</b>	<b>2,619</b>	<b>13,524</b>	<b>30.7</b>	<b>416.5</b>	<b>20,654</b>	<b>17,938</b>	<b>15.1</b>
Extra ordinary items	-	-	-	-	-	-	-	-	-	-
<b>Reported PAT</b>	<b>10,345</b>	<b>541</b>	<b>3,971</b>	<b>2,619</b>	<b>13,524</b>	<b>30.7</b>	<b>416.5</b>	<b>20,654</b>	<b>17,938</b>	<b>15.1</b>
<b>Adjusted EPS</b>	<b>4.2</b>	<b>0.2</b>	<b>1.6</b>	<b>1.1</b>	<b>5.6</b>	<b>30.7</b>	<b>416.5</b>	<b>8.5</b>	<b>7.4</b>	<b>15.1</b>
<b>Margins (%)</b>	<b>Q4FY20</b>	<b>Q1FY21</b>	<b>Q2FY21</b>	<b>Q3FY21</b>	<b>Q4FY21</b>	<b>bps</b>	<b>bps</b>	<b>FY21</b>	<b>FY20</b>	<b>bps</b>
EBIDTA	25.5	8.8	19.6	19.2	28.5	299	935	22.6	21.1	149
EBIT	23.9	3.5	16.7	15.1	27.2	330	1,214	20.0	18.4	159
EBT	24.4	4.6	17.5	16.1	27.9	359	1,188	20.9	19.2	168
PAT	17.8	3.2	12.5	11.4	19.6	176	817	14.7	13.9	80
Effective Tax rate	26.8	29.0	29.0	29.0	29.9	310	95	29.6	27.6	198

Source: Company, PL

## Analyst Meet Highlights

- Management indicated government initiative towards encouraging private participation and focus on Atmanirbhar Bharat will solve supply side constraints and benefit BEL in the long run.
- Ordering pipeline remains robust across segments such as electronic warfare system (~Rs150bn opportunity size), Army equipment's like Akash weapon system, QRSAM, LRSAM, MRSAM (Rs250-300bn) and naval equipment like surveillance system, navigation system (~Rs150-200bn).
- Despite pandemic OI flow came in at ~Rs155bn (up 17% YoY) in FY21. Given healthy pipeline, management guided for order inflows to the tune of Rs150-170bn (Army and Navy Rs40bn-50bn. Airforce Rs80-90bn and Non-defence Rs20-30bn).
- New Product:** During FY21, BEL diversified with new products such as ventilator, oxygen concentrator, dialysis, metros, aerospace, etc.
- BEL received its maiden order for 25,000 oxygen concentrators from ONGC, of which 1<sup>st</sup> lot is expected to be delivered in June. Going ahead, management expects healthy order inflows from this segment.
- The company entered into NOX Ltd for manufacturing for haemodialysis machine.
- In metro- Working on many new products for metro like automated fare collection, command control automated gate etc.
- Selected EOI for PSLV rocket and is participating in tenders like JV with Adani and BEML. Off 4 satellite contracts from ISRO, two were completed in FY21 and balance two to be completed in FY22.
- Management expects order for 3<sup>rd</sup> generation EVM machine stands Rs20bn from Election commission for 2024 elections.
- Export-** Export revenues stand at US\$52mn in FY21 and are expected to grow 15-17% for FY22, owing to healthy OB ~Rs12bn. Tender pipeline in export remain healthy and management wants OB to grow by US\$100mn in FY22.
- Services –** Services segment contributed 10% of total revenue and is expected to be in same range for FY22.
- Working capital improved in FY21 because of focus on cash collection (Rs180bn cash collection in FY21) thereby resulting in debtor's days coming down to 173 days from 195 days in FY20.
- Guidance for FY22-** Revenue to grow by 15-17% and margin to be in range of 20-22%. Employee cost as % of revenue to be ~12%.
- The Company plans to incur a capex plan of Rs8bn towards setting up new facilities in Hyderabad, Nagpur and Telangana.

## Financials

### Income Statement (Rs m)

Y/e Mar	FY20	FY21	FY22E	FY23E
<b>Net Revenues</b>	<b>129,211</b>	<b>140,638</b>	<b>164,921</b>	<b>192,866</b>
YoY gr. (%)	6.9	8.8	17.3	16.9
Cost of Goods Sold	71,052	78,278	92,356	108,005
Gross Profit	58,160	62,360	72,565	84,861
Margin (%)	45.0	44.3	44.0	44.0
Employee Cost	20,575	19,407	23,089	27,001
Other Expenses	7,071	6,909	10,720	11,572
<b>EBITDA</b>	<b>27,301</b>	<b>31,811</b>	<b>34,947</b>	<b>41,833</b>
YoY gr. (%)	(4.6)	16.5	9.9	19.7
Margin (%)	21.1	22.6	21.2	21.7
Depreciation and Amortization	3,496	3,663	3,890	4,525
<b>EBIT</b>	<b>23,805</b>	<b>28,148</b>	<b>31,056</b>	<b>37,307</b>
Margin (%)	18.4	20.0	18.8	19.3
Net Interest	33	61	64	67
Other Income	1,019	1,261	2,160	2,527
<b>Profit Before Tax</b>	<b>24,792</b>	<b>29,348</b>	<b>33,153</b>	<b>39,767</b>
Margin (%)	19.2	20.9	20.1	20.6
Total Tax	6,853	8,694	8,288	9,942
Effective tax rate (%)	27.6	29.6	25.0	25.0
<b>Profit after tax</b>	<b>17,938</b>	<b>20,654</b>	<b>24,865</b>	<b>29,825</b>
Minority interest	-	-	-	-
Share Profit from Associate	-	-	-	-
<b>Adjusted PAT</b>	<b>17,938</b>	<b>20,654</b>	<b>24,865</b>	<b>29,825</b>
YoY gr. (%)	(6.9)	15.1	20.4	19.9
Margin (%)	13.9	14.7	15.1	15.5
Extra Ord. Income / (Exp)	-	-	-	-
<b>Reported PAT</b>	<b>17,938</b>	<b>20,654</b>	<b>24,865</b>	<b>29,825</b>
YoY gr. (%)	(6.9)	15.1	20.4	19.9
Margin (%)	13.9	14.7	15.1	15.5
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	17,938	20,654	24,865	29,825
<b>Equity Shares O/s (m)</b>	<b>2,437</b>	<b>2,437</b>	<b>2,437</b>	<b>2,437</b>
<b>EPS (Rs)</b>	<b>7.4</b>	<b>8.5</b>	<b>10.2</b>	<b>12.2</b>

Source: Company Data, PL Research

### Balance Sheet Abstract (Rs m)

Y/e Mar	FY20	FY21	FY22E	FY23E
<b>Non-Current Assets</b>				
<b>Gross Block</b>	<b>37,644</b>	<b>40,567</b>	<b>48,567</b>	<b>56,567</b>
Tangibles	37,644	40,567	48,567	56,567
Intangibles	-	-	-	-
<b>Acc: Dep / Amortization</b>	<b>12,678</b>	<b>16,341</b>	<b>20,231</b>	<b>24,757</b>
Tangibles	12,678	16,341	20,231	24,757
Intangibles	-	-	-	-
<b>Net fixed assets</b>	<b>24,966</b>	<b>24,227</b>	<b>28,336</b>	<b>31,811</b>
Tangibles	24,966	24,227	28,336	31,811
Intangibles	-	-	-	-
Capital Work In Progress	7,059	7,936	7,936	7,936
Goodwill	-	-	-	-
Non-Current Investments	12,232	13,393	16,245	18,997
Net Deferred tax assets	4,974	4,634	4,634	4,634
Other Non-Current Assets	3,408	3,908	4,948	5,786
<b>Current Assets</b>				
Investments	-	-	-	-
Inventories	39,628	49,547	58,739	68,692
Trade receivables	67,329	84,960	85,849	89,828
Cash & Bank Balance	15,577	30,157	37,646	48,436
Other Current Assets	63,321	70,365	74,214	77,146
<b>Total Assets</b>	<b>234,137</b>	<b>285,898</b>	<b>315,562</b>	<b>350,561</b>
<b>Equity</b>				
Equity Share Capital	2,437	2,437	2,437	2,437
Other Equity	96,093	105,642	122,550	142,831
<b>Total Network</b>	<b>98,529</b>	<b>108,079</b>	<b>124,987</b>	<b>145,268</b>
<b>Non-Current Liabilities</b>				
Long Term borrowings	-	-	-	-
Provisions	-	-	-	-
Other non current liabilities	-	-	-	-
<b>Current Liabilities</b>				
ST Debt / Current of LT Debt	-	-	-	-
Trade payables	24,248	19,266	22,592	26,420
Other current liabilities	116,334	163,187	172,617	183,507
<b>Total Equity &amp; Liabilities</b>	<b>234,137</b>	<b>285,898</b>	<b>315,562</b>	<b>350,561</b>

Source: Company Data, PL Research

**Cash Flow (Rs m)**

Y/e Mar	FY20	FY21	FY22E	FY23E
PBT	24,792	29,348	33,153	39,767
Add. Depreciation	3,496	3,663	3,890	4,525
Add. Interest	30	61	64	67
Less Financial Other Income	1,019	1,261	2,160	2,527
Add. Other	(321)	689	-	-
Op. profit before WC changes	27,997	33,761	37,107	44,359
Net Changes-WC	3,013	22,597	(2,663)	(3,501)
Direct tax	(5,684)	(5,323)	(8,288)	(9,942)
<b>Net cash from Op. activities</b>	<b>25,325</b>	<b>51,035</b>	<b>26,155</b>	<b>30,916</b>
Capital expenditures	(7,264)	(4,664)	(10,645)	(10,515)
Interest / Dividend Income	692	600	-	-
Others	182	(21,622)	-	-
<b>Net Cash from Inv. activities</b>	<b>(6,389)</b>	<b>(25,686)</b>	<b>(10,645)</b>	<b>(10,515)</b>
Issue of share cap. / premium	-	-	-	-
Debt changes	(250)	(83)	-	-
Dividend paid	(9,793)	(10,227)	(7,957)	(9,544)
Interest paid	(30)	(58)	(64)	(67)
Others	(520)	(385)	-	-
<b>Net cash from Fin. activities</b>	<b>(10,593)</b>	<b>(10,754)</b>	<b>(8,021)</b>	<b>(9,611)</b>
<b>Net change in cash</b>	<b>8,343</b>	<b>14,594</b>	<b>7,489</b>	<b>10,790</b>
Free Cash Flow	18,053	46,357	18,155	22,916

Source: Company Data, PL Research

**Key Financial Metrics**


Y/e Mar	FY20	FY21	FY22E	FY23E
<b>Per Share(Rs)</b>				
EPS	7.4	8.5	10.2	12.2
CEPS	8.8	10.0	11.8	14.1
BVPS	40.4	44.4	51.3	59.6
FCF	7.4	19.0	7.5	9.4
DPS	2.4	4.0	3.3	3.9
<b>Return Ratio(%)</b>				
RoCE	25.2	27.2	26.7	27.6
ROIC	21.9	27.1	29.5	32.3
RoE	19.0	20.0	21.3	22.1
<b>Balance Sheet</b>				
Net Debt : Equity (x)	(0.2)	(0.3)	(0.3)	(0.3)
Net Working Capital (Days)	234	299	270	250
<b>Valuation(x)</b>				
PER	22.9	19.9	16.5	13.8
P/B	4.2	3.8	3.3	2.8
P/CEPS	19.2	16.9	14.3	12.0
EV/EBITDA	14.5	12.0	10.7	8.7
EV/Sales	3.1	2.7	2.3	1.9
Dividend Yield (%)	1.4	2.4	1.9	2.3

Source: Company Data, PL Research

**Quarterly Financials (Rs m)**

Y/e Mar	Q1FY21	Q2FY21	Q3FY21	Q4FY21
<b>Net Revenue</b>	<b>16,706</b>	<b>31,887</b>	<b>22,962</b>	<b>69,083</b>
YoY gr. (%)	(20.5)	16.3	1.1	19.0
Raw Material Expenses	8,234	17,540	11,811	40,693
Gross Profit	8,472	14,347	11,152	28,390
Margin (%)	50.7	45.0	48.6	41.1
<b>EBITDA</b>	<b>1,467</b>	<b>6,235</b>	<b>4,404</b>	<b>19,706</b>
YoY gr. (%)	(57.9)	14.5	24.1	32.9
Margin (%)	8.8	19.6	19.2	28.5
Depreciation / Depletion	888	914	945	917
<b>EBIT</b>	<b>579</b>	<b>5,321</b>	<b>3,459</b>	<b>18,789</b>
Margin (%)	3.5	16.7	15.1	27.2
Net Interest	1	3	2	56
Other Income	184	274	231	572
<b>Profit before Tax</b>	<b>762</b>	<b>5,592</b>	<b>3,688</b>	<b>19,305</b>
Margin (%)	4.6	17.5	16.1	27.9
Total Tax	221	1,622	1,070	5,782
Effective tax rate (%)	29.0	29.0	29.0	29.9
<b>Profit after Tax</b>	<b>541</b>	<b>3,971</b>	<b>2,619</b>	<b>13,524</b>
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
<b>Adjusted PAT</b>	<b>541</b>	<b>3,971</b>	<b>2,619</b>	<b>13,524</b>
YoY gr. (%)	(73.6)	17.0	21.7	30.7
Margin (%)	3.2	12.5	11.4	19.6
Extra Ord. Income / (Exp)	-	-	-	-
<b>Reported PAT</b>	<b>541</b>	<b>3,971</b>	<b>2,619</b>	<b>13,524</b>
YoY gr. (%)	(73.6)	17.0	21.7	30.7
Margin (%)	3.2	12.5	11.4	19.6
Other Comprehensive Income	-	-	-	-
<b>Total Comprehensive Income</b>	<b>541</b>	<b>3,971</b>	<b>2,619</b>	<b>13,524</b>
Avg. Shares O/s (m)	2,437	2,437	2,437	2,437
<b>EPS (Rs)</b>	<b>0.2</b>	<b>1.6</b>	<b>1.1</b>	<b>5.6</b>

Source: Company Data, PL Research

**Price Chart**
**Recommendation History**


No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	07-Apr-21	Accumulate	110	131
2	08-Jan-21	Accumulate	110	132
3	19-Nov-20	Accumulate	110	103
4	08-Oct-20	Hold	99	94
5	29-Jul-20	Hold	99	97
6	08-Jul-20	Hold	90	104
7	01-Jul-20	Hold	90	89

**Analyst Coverage Universe**

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	ABB India	Hold	1,337	1,388
2	Ahluwalia Contracts (India)	BUY	384	293
3	Apar Industries	BUY	696	524
4	Ashoka Buildcon	BUY	160	98
5	Bharat Electronics	Accumulate	110	131
6	BHEL	Sell	34	67
7	Capacite's Infraprojects	BUY	270	210
8	Container Corporation of India	Hold	607	634
9	Cummins India	Hold	796	772
10	Engineers India	BUY	129	84
11	GE T&D India	Hold	141	137
12	H.G. Infra Engineering	BUY	476	333
13	IRB Infrastructure Developers	BUY	179	106
14	ITD Cementation India	BUY	97	83
15	J.Kumar Infraprojects	BUY	272	177
16	Kalpataru Power Transmission	BUY	448	382
17	KEC International	Accumulate	420	417
18	KNR Constructions	Accumulate	253	227
19	Larsen & Toubro	BUY	1,604	1,416
20	NCC	BUY	111	83
21	PNC Infratech	BUY	295	256
22	Power Grid Corporation of India	BUY	205	170
23	Sadbhav Engineering	BUY	115	63
24	Siemens	Accumulate	2,101	2,064
25	Thermax	Accumulate	1,559	1,455
26	Triveni Turbine	BUY	98	102
27	Voltamp Transformers	BUY	1,466	1,058

**PL's Recommendation Nomenclature (Absolute Performance)**

<b>Buy</b>	: > 15%
<b>Accumulate</b>	: 5% to 15%
<b>Hold</b>	: +5% to -5%
<b>Reduce</b>	: -5% to -15%
<b>Sell</b>	: < -15%
<b>Not Rated (NR)</b>	: No specific call on the stock
<b>Under Review (UR)</b>	: Rating likely to change shortly

## ANALYST CERTIFICATION

### (Indian Clients)

We/I, Mr. Viral Shah- BE Chemical Engineering, MBA Finance, Mr. Nilesh Soni- BCom, MBA (Finance) Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### (US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

## DISCLAIMER

### Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at [www.plindia.com](http://www.plindia.com).

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is in the process of applying for certificate of registration as Research Analyst under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Viral Shah- BE Chemical Engineering, MBA Finance, Mr. Nilesh Soni- BCom, MBA (Finance) Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

### US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

---

### **Prabhudas Lilladher Pvt. Ltd.**

**3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209**

[www.plindia.com](http://www.plindia.com)